Clinical Research Directory
Browse clinical research sites, groups, and studies.
This is a Study Evaluating the Efficacy and Safety of LTG-001 for Acute Pain After Surgical Removal of Impacted Third Molars
Sponsor: Latigo Biotherapeutics
Summary
The goal of this clinical trial is to learn if LTG-001 works to treat pain after third molar removal surgery in adults. It will also learn about the safety of LTG-001. The main questions it aims to answer are: Does drug LTG-001 treat the acute pain after surgical removal of impacted third molars (wisdom teeth) over 12 hours? How tolerable is LTG-001 after surgical removal of impacted third molars (wisdom teeth) over 12 hours? Researchers in Part 1 will compare drug LTG-001 to a placebo (a look-alike substance that contains no drug) and in Part 2 to a placebo and a comparator to see if drug LTG-001 treats the post-surgical pain. Participants will: Take LTG-001 one time after the surgical removal of impacted third molars. Remain at the clinic for 12 hours after study dosing and return after a week for a safety check up. Report the pain relief during the 12 hours after dosing to record changes in the post-operative pain
Official title: A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study Evaluating the Efficacy and Safety of LTG 001 for Acute Pain After Surgical Removal of Impacted Third Molars
Key Details
Gender
All
Age Range
18 Years - 50 Years
Study Type
INTERVENTIONAL
Enrollment
250
Start Date
2024-12-19
Completion Date
2025-08-08
Last Updated
2026-05-22
Healthy Volunteers
No
Conditions
Interventions
LTG-001 High Dose
LTG-001 High Dose
LTG-001 Mid Dose
LTG-001 Mid Dose
LTG-001 Low Dose
LTG-001 Low Dose
Placebo
Placebo
Suzetrigine
Active comparator - Nav1.8 inhibitor
Locations (1)
JBR Clinical Research
Salt Lake City, Utah, United States